Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-4

Thanks Dr T an excellent summary.

For those playing at home, and new to the Race game, this background may assist.

Background:
The original formulation of Bisantrene (RC110 - circa 40 years old) could only be administered via a central line. This requires hospitalisation so a central venous catheter could be placed in a vein and threaded to the heart by a qualified doctor with suitable equipment to acquire the right location. i.e. it is expensive, time consuming and not easy access for patients.

Race Oncology were able to develop a new formulation of Bisantrene (RC220 – signed off for human use in 2024) which can be administered via a peripheral Intravenous line. This only requires a visit to a clinic and can be administered in the arm by a suitably qualified nurse or practitioner. i.e. it is much easier, and cheaper, for patients to be treated.

Research to date indicates RC220 performs the same way as RC110. It is the same molecule. However, because of the reformulation, the FDA require it to again be tested in humans. Race has approval to start these in human trials. A number of trials are in planning and expect to commence within the next 12 months.

Cheers